Bioventus (NYSE:BVS) Hits New 1-Year High at $11.52

Bioventus Inc. (NYSE:BVS) shares hit a new 52-week high during trading on Monday . The company traded as high as $11.52 and last traded at $11.52, with a volume of 1104 shares. The stock had previously closed at $11.17.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Canaccord Genuity Group raised their target price on Bioventus from $8.00 to $12.00 and gave the company a “buy” rating in a report on Tuesday, August 13th. Craig Hallum lifted their price objective on shares of Bioventus from $9.00 to $12.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th.

Bioventus Price Performance

The company has a debt-to-equity ratio of 1.82, a quick ratio of 0.96 and a current ratio of 1.33. The stock has a market cap of $900.12 million, a PE ratio of -32.49 and a beta of 0.89. The business has a 50 day moving average price of $8.47 and a two-hundred day moving average price of $6.54.

Bioventus (NYSE:BVS) last announced its earnings results on Tuesday, August 6th. The company reported $0.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.07 by $0.12. The firm had revenue of $151.22 million during the quarter, compared to analyst estimates of $137.70 million. Bioventus had a positive return on equity of 14.39% and a negative net margin of 7.82%. During the same period last year, the firm posted $0.14 EPS. Research analysts expect that Bioventus Inc. will post 0.4 earnings per share for the current fiscal year.

Insider Buying and Selling at Bioventus

In related news, Director John A. Bartholdson purchased 80,000 shares of the stock in a transaction that occurred on Friday, August 16th. The shares were bought at an average price of $8.55 per share, with a total value of $684,000.00. Following the acquisition, the director now owns 6,913,857 shares of the company’s stock, valued at approximately $59,113,477.35. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, Director John A. Bartholdson bought 80,000 shares of the firm’s stock in a transaction on Friday, August 16th. The stock was acquired at an average cost of $8.55 per share, with a total value of $684,000.00. Following the completion of the transaction, the director now directly owns 6,913,857 shares of the company’s stock, valued at approximately $59,113,477.35. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Anthony D’adamio sold 5,904 shares of the business’s stock in a transaction on Friday, June 21st. The shares were sold at an average price of $5.57, for a total value of $32,885.28. Following the completion of the sale, the senior vice president now owns 95,576 shares in the company, valued at $532,358.32. The disclosure for this sale can be found here. Corporate insiders own 32.90% of the company’s stock.

Hedge Funds Weigh In On Bioventus

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. LSV Asset Management purchased a new stake in shares of Bioventus during the 1st quarter valued at approximately $1,170,000. Lazard Asset Management LLC purchased a new position in shares of Bioventus in the first quarter valued at $40,000. Quadrature Capital Ltd bought a new stake in shares of Bioventus during the 4th quarter valued at $85,000. GSG Advisors LLC boosted its stake in Bioventus by 55.8% in the 1st quarter. GSG Advisors LLC now owns 26,511 shares of the company’s stock worth $133,000 after purchasing an additional 9,500 shares during the period. Finally, HB Wealth Management LLC bought a new position in Bioventus in the 2nd quarter worth about $60,000. Institutional investors own 62.94% of the company’s stock.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.